Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

pharmaceuticals

  • Home
  •  
  • pharmaceuticals



  • Most Read
  • Latest Comments
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • News

    Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials

    Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the

    Read More
    Public
  • MedAdvisor engaged with $4m deal to promote COVID-19 vaccination
    • News

    MedAdvisor engaged with $4m deal to promote COVID-19 vaccination

    While Australia enjoys the freedom of restrictions opening up and a substantial decrease in the COVID-19 deaths, vaccination rates across various States in the US remain dangerously low which has prompted one big pharma company to engage medtech company MedAdvisor (ASX: MDR) to slay the anti-vaxxers.  For the unnamed big pharma company which has a

    Read More
    Public
  • A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial
    • News

    A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial

    Whilst key opinion leaders worldwide are following the Pharmaxis (ASX: PXS) story, Professor Fiona Wood has become an integral part of it.  Following the news out of Rochester University that their myelofibrosis drug, PXS-5505, has a potential significant disease modifying role in other cancers comes another key announcement for the company, this time regarding theirRead More
    Public
  • Cancer drug development company gathering momentum as more researchers worldwide take notice
    • News

    Cancer drug development company gathering momentum as more researchers worldwide take notice

    With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead More
    Public
  • Over half a century since its launch, the contraceptive pill is getting a shake up
    • News

    Over half a century since its launch, the contraceptive pill is getting a shake up

    Bloating, weight gain, mood swings, headaches. Just a handful of the not so lovely side effects bestowed upon women by the contraceptive pill. After half a century, I think we can all agree that the pill is long overdue for a shake up. With more women than ever increasingly aware of what they put into

    Read More
    Public
  • How Incannex is helping you catch some zzz’s
    • News

    How Incannex is helping you catch some zzz’s

    Unsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte*  People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial

    Read More
    Public
  • 1
  • 2
  • 3
  • 4
  • 5

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.